Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma

- Kritikos, Vicky, Harvey, Erin S., Thomas, Dennis, Gibson, Peter G., Australian Mepolizumab Registry Investigators,, Stevens, Sean, Katelaris, Constance H., Langton, David, Rimmer, Janet, Farah, Claude S., Gillman, Andrew, Hew, Mark, Radhakrishna, Naghmeh

Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry

- Thomas, Dennis, Harvey, Erin S., Bardin, Philip, Peters, Matthew, Reynolds, Paul N., Langton, David, Baraket, Melissa, Bowden, Jeffrey J., Bowler, Simon, Chien, Jimmy, Chung, Li Ping, Farah, Claude S., McDonald, Vanessa M., Wark, Peter A. B., Gibson, Peter G., Katsoulotos, GP, Lee, J, Radhakrishna, N, Reddel, HK, Rimmer, J, Sivakumaran, P, Wark, PAB, Gibson, PG, Stevens, Sean, Upham, John W., Katelaris, Constance H., Kritikos, Vicky, Gillman, Andrew, Harrington, John, Hew, Mark

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions

- Gibson, Peter G., Prazma, Charlene M., Chupp, Geoffrey L., Bradford, Eric S., Forshag, Mark, Mallett, Stephen A., Yancey, Steve W., Smith, Steven G., Bel, Elisabeth H.

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

- Khatri, Sumita, Moore, Wendy, Gibson, Peter G., Leigh, Richard, Bourdin, Arnaud, Maspero, Jorge, Barros, Manuel, Buhl, Roland, Howarth, Peter, Albers, Frank C., Bradford, Eric S., Gilson, Martyn, Price, Robert G., Yancey, Stephen W., Ortega, Hector